Annual report pursuant to Section 13 and 15(d)

Reverse Merger - Summary of Pro Forma Results of Operation (Detail)

v3.19.1
Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]    
Net loss applicable to common shareholders $ (12,687) $ (20,111)
Net loss per share-basic and diluted $ (3.61) $ (41.95)
Weighted average shares 3,510,217 479,442